CATALOGO DEI PRODOTTI DELLA RICERCA

PIGHI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.799
NA - Nord America 1.745
AS - Asia 1.366
SA - Sud America 238
AF - Africa 78
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.231
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.704
RU - Federazione Russa 915
SG - Singapore 623
CN - Cina 255
IT - Italia 211
BR - Brasile 203
HK - Hong Kong 202
DE - Germania 115
FR - Francia 111
GB - Regno Unito 99
VN - Vietnam 95
IE - Irlanda 91
KR - Corea 73
SE - Svezia 62
FI - Finlandia 54
ES - Italia 37
TG - Togo 30
BJ - Benin 29
PL - Polonia 29
CA - Canada 24
NL - Olanda 23
IN - India 19
JP - Giappone 16
AT - Austria 14
ID - Indonesia 13
MX - Messico 13
AR - Argentina 11
BD - Bangladesh 10
TR - Turchia 9
BE - Belgio 8
IQ - Iraq 8
LT - Lituania 8
TW - Taiwan 8
EC - Ecuador 6
ZA - Sudafrica 6
AE - Emirati Arabi Uniti 5
PE - Perù 5
UA - Ucraina 5
AU - Australia 4
BH - Bahrain 4
CO - Colombia 4
MA - Marocco 4
UZ - Uzbekistan 4
VE - Venezuela 4
DZ - Algeria 3
IR - Iran 3
PK - Pakistan 3
PY - Paraguay 3
TH - Thailandia 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BY - Bielorussia 2
CH - Svizzera 2
DK - Danimarca 2
JO - Giordania 2
KG - Kirghizistan 2
NP - Nepal 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
BN - Brunei Darussalam 1
BO - Bolivia 1
CL - Cile 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
EU - Europa 1
GH - Ghana 1
IL - Israele 1
IS - Islanda 1
LK - Sri Lanka 1
MG - Madagascar 1
NO - Norvegia 1
PA - Panama 1
PR - Porto Rico 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
TN - Tunisia 1
Totale 5.231
Salva come PNG Salva come JPEG
Città #
Dallas 461
Moscow 301
Singapore 257
Chandler 244
Hong Kong 198
Ashburn 197
Dublin 88
Beijing 60
Munich 53
Los Angeles 44
Verona 41
Milan 39
London 37
The Dalles 35
Columbus 33
Buffalo 32
Ho Chi Minh City 31
Lomé 30
Cotonou 29
New York 29
Seattle 27
Madrid 26
Redondo Beach 26
Helsinki 25
Hanoi 22
Lawrence 22
Princeton 22
Warsaw 21
Redmond 20
Santa Clara 18
Seoul 18
Sindelfingen 18
São Paulo 18
Turku 18
Amsterdam 17
Boston 17
Wilmington 16
Tokyo 14
Frankfurt am Main 13
Brooklyn 11
Poplar 11
Lappeenranta 10
Montreal 10
Denver 9
Jakarta 9
Philadelphia 9
Tianjin 9
Vienna 9
Brussels 8
Paris 8
Ann Arbor 7
Atlanta 7
Chennai 7
Haiphong 7
Nuremberg 7
Shenzhen 7
Taipei 7
Chicago 6
Guangzhou 6
Houston 6
Orem 6
Pescantina 6
Rome 6
Ancona 5
Bonndorf 5
Brasília 5
Curitiba 5
Hyderabad 5
Johannesburg 5
Mexico City 5
Phoenix 5
Rio de Janeiro 5
San Francisco 5
Southend 5
Stockholm 5
Wroclaw 5
Zhengzhou 5
Ankara 4
Belo Horizonte 4
Bentivoglio 4
Bexley 4
Biên Hòa 4
Caracas 4
Caxias do Sul 4
Charlotte 4
Des Moines 4
Lima 4
Ottawa 4
Padova 4
Peschiera del Garda 4
Querétaro 4
Salt Lake City 4
Tappahannock 4
Tashkent 4
Toronto 4
Washington 4
Woodbridge 4
Xi'an 4
Aracaju 3
Bologna 3
Totale 2.965
Salva come PNG Salva come JPEG
Nome #
A Comparative Evaluation of the Chemiluminescence Immunoassay and ELISA for the Detection of Islet Autoantibodies in Type 1 Diabetes 212
Clinical assessment of FREND COVID-19 Ag test in an unselected population referred for routine SARS-CoV-2 testing 145
Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA 141
Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers 137
Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination 130
Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers 130
Clinical Assessment of the DiaSorin LIAISON SARS-CoV-2 Ag Chemiluminescence Immunoassay 129
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series 124
Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals 120
Analytical evaluation of the novel Mindray high sensitivity cardiac troponin I immunoassay on CL-1200i 116
Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity 114
Clinical performance of the Roche Elecsys SARS-CoV-2 antigen fully automated electrochemiluminescence immunoassay 111
Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay 110
Real-world assessment of Fluorecare SARS-CoV-2 Spike Protein Test Kit 107
The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters 106
Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination 104
Performance of Fujirebio Espline SARS-CoV-2 rapid antigen test for identifying potentially infectious individuals 101
Evaluation of indoor hospital acclimatization of body temperature before COVID-19 fever screening 96
Correlation Between Time to Positive Result of SARS-CoV-2 Rapid Antigen Self-Test and Viral Antigen Concentration 94
Improved potassium reliability in whole blood through hemolysis detection on the novel GEM Premier 7000 blood gas analyzer 91
Variation of Forehead Temperature during Routine Working Shift in Hospital Laboratory Personnel: Implications for SARS-CoV-2 Screening 90
Association between viral load and positivization time of a SARS-CoV-2 rapid antigen test in routine nasopharyngeal specimens 89
Humoral response post-BNT162b2 single booster in pre-vaccination baseline SARS-CoV-2 seronegative and seropositive subjects 89
Are anti-SARS-CoV-2 S/N IgG/IgM antibodies always predictive of previous SARS-CoV-2 infection? 89
Clinical performance of Fujirebio Lumipulse G SARSCoV- 2 Ag chemiluminescent immunoassay 87
Clinical assessment of SNIBE Maglumi SARS-CoV-2 antigen fully-automated chemiluminescent immunoassay 86
Monoclonal gammopathy in SARS-CoV-2 infection 84
Cellular immunity against SARS-CoV-2 depends on the serological status 82
Three-month ad interim analysis of total anti-SARS-CoV-2 antibodies in healthy recipient of a single BNT162b2 vaccine booster 81
Accuracy of screening for hemolysis in plasma samples using a commercial urine dipstick 80
Preanalytical Impact of Incomplete K2EDTA Blood Tube Filling in Molecular Biology Testing 80
Longitudinal monitoring of anti-SARS-CoV-2 RBD IgG antibodies after BNT162b2 vaccination in healthcare workers 80
Cost-effectiveness analysis of different COVID-19 screening strategies based on rapid or laboratory-based SARS-CoV-2 antigen testing 78
Effect of syringe underfilling on the quality of venous blood gas analysis 78
Clinical assessment of Ortho VITROS SARS-CoV-2 antigen chemiluminescence immunoassay 77
Analytical validation of hemolysis detection on GEM Premier 7000 72
Positivization time of a COVID-19 rapid antigen self-test predicts SARS-CoV-2 viral load: a proof of concept 71
Impact of the COVID-19 pandemic on the volume of laboratory testing 70
Can cellular and humoral immunity predict response to BNT162b2 bivalent booster? 70
Serum C reactive protein predicts humoral response after BNT162b2 booster administration 70
Limitations of hemolysis-based correction for potassium measurement in hemolyzed whole blood samples 69
Evaluating the accuracy of ChatGPT in classifying normal and abnormal blood cell morphology 68
SARS-CoV-2 Omicron infection is associated with high nasopharyngeal viral load 68
Real-world assessment of the clinical performance of COVID-VIRO ALL IN rapid SARS-CoV-2 antigen test 64
Correlation between basal humoral immunogenicity and side effects after receiving the bivalent formulation of a mRNA-based vaccine 64
Methadone metabolite (EDDP) crystals in urine: a case report 63
Impact of an air bubble within the syringe on test results obtained with a modern blood gas analyzer 61
Generative artificial intelligence (AI) for reporting the performance of laboratory biomarkers: not ready for prime time 59
Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2 51
Early kinetics of cellular immunity in recipients of bivalent BNT162b2 vaccine: a proof-of-concept study 51
Effect of exogenous lipids contamination on blood gas analysis 51
Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers 50
Reliability of a single-nostril nasopharyngeal swab for diagnosing SARS-CoV-2 infection 49
Monitoring humoral and cellular immunity over 6 months after mRNA-based bivalent COVID-19 vaccine administration 48
Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster 47
Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers 46
Performance assessment of ChatGPT in classification of urine particles 45
Is mixing of blood gas syringes after collection really necessary? 44
Vaccination time does not influence total anti-SARS-CoV-2 antibodies response 41
The incremental impact of comorbidities in COVID-19-related deaths compared to patients dying from cancer or cardiovascular disease 39
Humoral response is enhanced after ipsilateral double intramuscular injection of BNT162b2 COVID-19 vaccine 39
Evaluation of freely available artificial intelligence (AI) tools for diagnostic support in a complex clinical and laboratory presentations: a pilot study 38
Evaluation of circadian rhythm of SARS-CoV-2 interferon-gamma release assay (IGRA) in healthy vaccinated individuals: a case-series 35
Update on Patient Self-Testing with Portable and Wearable Devices: Advantages and Limitations 33
Urine dipstick for screening plasma glucose and bilirubin in low resource settings: a proof-of-concept study 32
Differential diagnosis of lymphocytosis in routine laboratory practice: the contribution of Sysmex- XN9100 28
Uso de una tira reactiva paraorina en la evaluación de las concentraciones de glucosa y bilirrubina en plasma en entornos con recursos limitados: un estudio de prueba de concepto 28
Evaluation of the acceptability of proposed hemolysis limits for Werfen ACL-TOP 750 CTS 27
Totale 5.359
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.635
article - articoli 21.289
book - libri 0
conference - conferenze 53
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 293
Totale 43.270
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202124 0 0 0 0 0 0 0 0 2 3 2 17
2021/2022205 29 37 7 8 10 4 4 6 14 8 26 52
2022/2023621 36 51 58 116 31 126 23 54 63 9 29 25
2023/2024433 19 30 29 45 66 48 43 71 4 25 38 15
2024/20251.527 65 84 90 185 61 62 64 87 181 139 225 284
2025/20262.549 333 281 405 672 858 0 0 0 0 0 0 0
Totale 5.359